# LL-37 Peptide

> LL-37 is a human cathelicidin antimicrobial peptide that acts on innate immune defense, barrier function, wound response, and inflammation signaling.

Canonical: https://pepflow.app/peptides/ll-37/

The Barrier Defender

The only human cathelicidin antimicrobial peptide, central to innate immune defense, barrier biology, wound-response signaling, and inflammation research.

Inflammation  Wound repair  Skin barrier

Tier D

Evidence Preliminary

Safety Limited Data

FDA status Not Approved

Topical 503A Flagged

Last reviewed October 25, 2026 45 citations [How to read these labels](<https://pepflow.app/peptide-label-legend/>)

## What is LL-37?

LL-37 is the active C-terminal peptide generated from human cathelicidin hCAP18. It is produced at epithelial and immune barriers and is widely reviewed as a multifunctional antimicrobial and immune-modulating peptide.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16716248/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/20049649/>)

The molecule matters because it sits at the interface of microbes, skin and mucosal barriers, neutrophils, epithelial cells, and inflammatory signaling. That makes it relevant to wound, infection, rosacea, sepsis-biomarker, vitamin D, and immune-defense literature.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/19068548/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/23246832/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/26086941/>)

LL-37 is not the same as the full hCAP18 precursor. The name refers to the mature 37-amino-acid peptide generated from human cathelicidin, while cathelicidin or hCAP18 can describe the broader precursor system. That naming distinction matters when comparing biomarker studies, topical formulations, and peptide products.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16716248/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/23246832/>)

## What LL-37 is investigated for

LL-37 evidence is grouped by practical use case and topical, injectable, vaginal, and intratracheal route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

### ### Antimicrobial defense Topical, Injectable 50% Emerging

LL-37 is central to antimicrobial-defense biology; therapeutic claims need route-specific human trials and should not be generalized to chronic systemic injection.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16716248/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/19068548/>)

#### Human evidence

Human evidence is strongest for endogenous cathelicidin measurement, vitamin-D-linked LL-37 biology, and limited route-specific trials rather than systemic injectable treatment protocols.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16716248/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/19068548/>)

#### Animal / mechanistic evidence

Reviews support LL-37 as the only human cathelicidin and a multifunctional antimicrobial peptide.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16716248/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/19068548/>)

### ### Skin and barrier inflammation Topical 45% Preliminary

Skin-inflammatory relevance is context dependent; barrier-immunity findings should not be generalized into cosmetic or systemic anti-inflammatory benefit.[\[8\]](<https://pubmed.ncbi.nlm.nih.gov/26545199/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/23246832/>)

#### Human evidence

Human studies often involve biomarkers or related interventions such as vitamin D rather than direct LL-37 treatment.[\[8\]](<https://pubmed.ncbi.nlm.nih.gov/26545199/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/23246832/>)

#### Animal / mechanistic evidence

LL-37 is involved in epithelial immunity and inflammatory signaling at barrier surfaces.[\[8\]](<https://pubmed.ncbi.nlm.nih.gov/26545199/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/23246832/>)

### ### Wound healing Topical 42% Preliminary

Topical wound healing is a legitimate LL-37 research area, but it remains adjunctive and should not replace standard wound care or infection management.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25041740/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/34687253/>) [\[23\]](<https://pubmed.ncbi.nlm.nih.gov/37480520/>)

#### Human evidence

Topical LL-37 has been studied in hard-to-heal venous leg ulcers and diabetic foot ulcers, with published randomized trial signals and ongoing registry context.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25041740/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/34687253/>) [\[23\]](<https://pubmed.ncbi.nlm.nih.gov/37480520/>) [\[40\]](<https://clinicaltrials.gov/study/NCT04098562>)

#### Animal / mechanistic evidence

Barrier and wound literature links LL-37 with epithelial repair signaling, keratinocyte activity, angiogenesis, and antimicrobial defense at injured surfaces.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/19068548/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/23246832/>)

### ### Gut barrier support Topical 30% Limited

Gut-barrier support remains a barrier-immunity hypothesis, not a validated GI treatment.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/20049649/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/23246832/>)

#### Human evidence

No controlled human trial establishes exogenous LL-37 as a treatment for gut-barrier dysfunction or intestinal-permeability outcomes.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/20049649/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/23246832/>)

#### Animal / mechanistic evidence

Reviews describe LL-37 activity at epithelial barrier surfaces, including antimicrobial and immune-signaling roles relevant to mucosal defense.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/20049649/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/23246832/>)

## Evidence snapshot

### Overall confidence

Preliminary

42%

LL-37 has deep endogenous cathelicidin biology but weaker exogenous treatment evidence. Route and context matter because antimicrobial, barrier, and inflammatory effects can diverge.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16716248/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/23246832/>) [\[40\]](<https://clinicaltrials.gov/study/NCT04098562>)

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

40%

### Human evidence

Preliminary

Published human literature is strongest as biomarker and disease-context evidence, with topical trial activity still early. It does not establish broad clinical efficacy for LL-37 products.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/26086941/>) [\[40\]](<https://clinicaltrials.gov/study/NCT04098562>)

48%

### Animal / preclinical

Preliminary

Preclinical literature supports antimicrobial, immune, wound, and barrier-response biology across models. Those models do not settle route-specific treatment effects.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/19068548/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/20049649/>)

68%

### Mechanism support

Moderate

Cathelicidin biology gives LL-37 a well-established innate-immunity mechanism. The practical caveat is that inflammatory effects can shift by tissue, dose, and disease context.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16716248/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/23246832/>)

## Forms & administration

LL-37 has topical wound preparations and separate injectable research presentations. Vaginal and intratracheal formulations remain experimental, with animal-only evidence. Each route requires its own preparation and amount; direct airway delivery is distinct from nebulization and does not establish a human inhaled product.[\[40\]](<https://clinicaltrials.gov/study/NCT04098562>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/23246832/>) [\[36\]](<https://api.fda.gov/drug/drugsfda.json?search=%22LL-37%22&limit=1>) [\[42\]](<https://pubmed.ncbi.nlm.nih.gov/37326833/>) [\[43\]](<https://pubmed.ncbi.nlm.nih.gov/24549217/>) [\[44\]](<https://pubmed.ncbi.nlm.nih.gov/30741829/>)

Topical Injectable Vaginal Intratracheal

## Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

### Typical Range

Common injectable protocols use 500 mcg-1.6 mg per dose. Topical amounts depend on the product.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/23246832/>) [\[36\]](<https://api.fda.gov/drug/drugsfda.json?search=%22LL-37%22&limit=1>)

### Frequency

Injectable protocols usually use 1-2 doses daily. Topical schedules follow the wound-care plan.[\[40\]](<https://clinicaltrials.gov/study/NCT04098562>)

### Timing Considerations

Use injections in the morning or evening. Apply topical products during dressing changes.[\[40\]](<https://clinicaltrials.gov/study/NCT04098562>)

### Cycle Length

Injectable cycles commonly run 2-4 weeks.[\[40\]](<https://clinicaltrials.gov/study/NCT04098562>)

[Full LL-37 dosage guide](<https://pepflow.app/peptides/ll-37/dosage/>)

## What to expect

### First week

Topical wound or skin use may first show changes in redness, drainage, pain, surface irritation, or barrier comfort.[\[40\]](<https://clinicaltrials.gov/study/NCT04098562>)

### Weeks 2-4

Wound size, barrier comfort, flare frequency, and pain are the clearest short-course patterns for topical use; injectable immune-support expectations remain much less concrete.[\[40\]](<https://clinicaltrials.gov/study/NCT04098562>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/23246832/>)

### After stopping

Barrier comfort and wound trajectory may hold, fade, or return toward baseline depending on wound care and other skin-care changes.[\[40\]](<https://clinicaltrials.gov/study/NCT04098562>)

## Safety profile

Topical LL-37 safety centers on local irritation and wound-care context. Injectable or systemic exposure is a different risk category, with added immune-activation, sterility, product-quality, and unknown exposure concerns.[\[40\]](<https://clinicaltrials.gov/study/NCT04098562>) [\[36\]](<https://api.fda.gov/drug/drugsfda.json?search=%22LL-37%22&limit=1>) [\[39\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)

### Common side effects

- Local irritation [\[40\]](<https://clinicaltrials.gov/study/NCT04098562>)

### Cautions

- Active infection or complex wounds[\[40\]](<https://clinicaltrials.gov/study/NCT04098562>)
- Immune activation uncertainty[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/23246832/>)
- Injectable product quality[\[38\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[39\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)

### What we don't know

Injectable LL-37 lacks a mature human pharmacokinetic and long-term systemic safety base.[\[36\]](<https://api.fda.gov/drug/drugsfda.json?search=%22LL-37%22&limit=1>)

## Who LL-37 is not for

Route-specific avoid and medical-review notes:

- **Pregnancy or breastfeeding**

  Avoid exogenous LL-37 because route-specific reproductive safety is not established.[\[36\]](<https://api.fda.gov/drug/drugsfda.json?search=%22LL-37%22&limit=1>)
- **Untreated infected or complex wounds**

  Medical wound care should come first; topical peptide use should not delay evaluation.[\[40\]](<https://clinicaltrials.gov/study/NCT04098562>)

## Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

### Theoretical interactions

- **Immunosuppressive therapy**

  Immunosuppressive therapy could change infection and inflammation context for topical or injectable LL-37; this is a theoretical route-specific immune caution.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/19068548/>)

## Regulatory status

### United States

LL-37 has no FDA-approved topical or injectable drug use as of 2026-06-21. FDA's compounding materials flag cathelicidin LL-37 in a withdrawn Category 2 safety-risk context, so research-market availability should not be read as a cleared human-use product.[\[36\]](<https://api.fda.gov/drug/drugsfda.json?search=%22LL-37%22&limit=1>) [\[38\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[39\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)

| Route | FDA drug approval | 503A compounding |
| --- | --- | --- |
| Topical | Not Approved · As of 2026-06-21, LL-37 was not FDA-approved as a topical wound drug or injectable/systemic drug. Topical trial activity and research-market products do not create FDA approval.[\[36\]](<https://api.fda.gov/drug/drugsfda.json?search=%22LL-37%22&limit=1>) [\[39\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) | Flagged · FDA lists cathelicidin LL-37 among nominated bulk substances withdrawn after Category 2 safety-risk concerns; that compounding context is separate from topical research and does not approve compounded LL-37.[\[38\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[39\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) |
| Injectable | Not Approved · As of 2026-06-21, LL-37 was not FDA-approved as a topical wound drug or injectable/systemic drug. Topical trial activity and research-market products do not create FDA approval.[\[36\]](<https://api.fda.gov/drug/drugsfda.json?search=%22LL-37%22&limit=1>) [\[39\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) | Flagged · FDA lists cathelicidin LL-37 among nominated bulk substances withdrawn after Category 2 safety-risk concerns; that compounding context is separate from topical research and does not approve compounded LL-37.[\[38\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[39\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) |

### Topical

FDA drug approval

Not Approved

As of 2026-06-21, LL-37 was not FDA-approved as a topical wound drug or injectable/systemic drug. Topical trial activity and research-market products do not create FDA approval.[\[36\]](<https://api.fda.gov/drug/drugsfda.json?search=%22LL-37%22&limit=1>) [\[39\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)

503A compounding

Flagged

FDA lists cathelicidin LL-37 among nominated bulk substances withdrawn after Category 2 safety-risk concerns; that compounding context is separate from topical research and does not approve compounded LL-37.[\[38\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[39\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)

### Injectable

FDA drug approval

Not Approved

As of 2026-06-21, LL-37 was not FDA-approved as a topical wound drug or injectable/systemic drug. Topical trial activity and research-market products do not create FDA approval.[\[36\]](<https://api.fda.gov/drug/drugsfda.json?search=%22LL-37%22&limit=1>) [\[39\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)

503A compounding

Flagged

FDA lists cathelicidin LL-37 among nominated bulk substances withdrawn after Category 2 safety-risk concerns; that compounding context is separate from topical research and does not approve compounded LL-37.[\[38\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[39\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)

### International

EU/Europe, UK, Canada, and Australia should be checked by local product and claim; topical research activity does not equal therapeutic market authorization.

### Sports & competition

WADA's 2026 Prohibited List does not specifically name LL-37, but tested athletes should treat systemic use of a non-approved pharmacological substance as an S0 risk unless cleared through anti-doping review.[\[41\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)

## How it works

LL-37 is the active human cathelicidin peptide at barrier surfaces. It can damage microbes directly, but its broader role is signaling: recruiting immune cells, changing inflammatory tone, and influencing epithelial and wound-response behavior.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16716248/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/19068548/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/20049649/>)

That dual action is why route matters. Topical LL-37 logic is tied to local skin or wound exposure, while injectable or systemic use would expose immune-active pathways more broadly. Endogenous host-defense biology should not be read as proof that added LL-37 improves immunity or healing in people.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/23246832/>) [\[22\]](<https://pubmed.ncbi.nlm.nih.gov/37276169/>) [\[40\]](<https://clinicaltrials.gov/study/NCT04098562>)

## Research gaps & open questions

What the current literature has not yet settled about LL-37:

01

Completed human trials need to show whether topical LL-37 actually improves wound closure, infection control, pain, or scarring—not only laboratory measures.[\[40\]](<https://clinicaltrials.gov/study/NCT04098562>)

02

Human studies need to show how injectable LL-37 is absorbed and cleared, how strongly it activates the immune system, and whether repeated exposure is safe.[\[36\]](<https://api.fda.gov/drug/drugsfda.json?search=%22LL-37%22&limit=1>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/23246832/>)

03

Trials need to separate conditions where LL-37 may help fight infection from conditions where it could worsen harmful inflammation.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/19068548/>)

## Common questions

### What is LL-37?

LL-37 is the active human cathelicidin antimicrobial peptide, a barrier-defense signal involved in microbial responses, inflammation, and wound biology.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16716248/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/19068548/>)

### Is LL-37 an antibiotic?

No. LL-37 has antimicrobial peptide biology, but topical or injectable LL-37 is not a substitute for antibiotics, infection care, or wound management.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/20049649/>) [\[40\]](<https://clinicaltrials.gov/study/NCT04098562>)

### Is LL-37 FDA-approved?

No. LL-37 has no FDA-approved topical or injectable drug use as of 2026-06-21; topical trials and research-market products do not create market authorization.[\[36\]](<https://api.fda.gov/drug/drugsfda.json?search=%22LL-37%22&limit=1>) [\[39\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)

## Myths & misconceptions

### Myth

Because LL-37 is natural, exogenous LL-37 is automatically safe.

### Reality

Endogenous barrier biology does not establish safety for concentrated topical products or systemic injections.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/23246832/>) [\[36\]](<https://api.fda.gov/drug/drugsfda.json?search=%22LL-37%22&limit=1>)

### Myth

LL-37 is a simple immune booster.

### Reality

LL-37 is immune-active and context-dependent, which is different from a predictable immune boost.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/19068548/>)

## History & discovery

LL-37's history starts in human cathelicidin biology: hCAP18 processing produces a 37-amino-acid peptide that became a model for barrier defense, immune signaling, and wound biology.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16716248/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/19068548/>)

Reviews established LL-37 as the mature active peptide from hCAP18, the only human cathelicidin, distinguishing it from conventional antibiotics or generic antimicrobial products.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16716248/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/20049649/>)

Research expanded from direct antimicrobial activity into chemotaxis, epithelial activation, angiogenesis, inflammation control, and other host-defense functions.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/19068548/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/20049649/>)

Topical LL-37 cream moved into diabetic-foot-ulcer testing, a route-specific therapeutic question separate from injectable compounding discussions.[\[40\]](<https://clinicaltrials.gov/study/NCT04098562>)

## Published research 45 citations

- [\[1\] **LL-37, the only human member of the cathelicidin family of antimicrobial peptides.** Biochimica et biophysica acta, 2006 Sep. review.](<https://pubmed.ncbi.nlm.nih.gov/16716248/>)
- [\[2\] **The roles of cathelicidin LL-37 in immune defences and novel clinical applications.** Current opinion in hematology, 2009 Jan. review.](<https://pubmed.ncbi.nlm.nih.gov/19068548/>)
- [\[3\] **Cathelicidin LL-37: a multitask antimicrobial peptide.** Archivum immunologiae et therapiae experimentalis, 2010 Feb. review.](<https://pubmed.ncbi.nlm.nih.gov/20049649/>)
- [\[4\] **A comprehensive summary of LL-37, the factotum human cathelicidin peptide.** Cellular immunology, 2012 Nov. review.](<https://pubmed.ncbi.nlm.nih.gov/23246832/>)
- [\[5\] **Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial.** Wound repair and regeneration : official publication of the Wound Healing Society \[and\] the European Tissue Repair Society, 2014 Sep-Oct. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/25041740/>)
- [\[6\] **Effect of Cholecalciferol Supplementation on Vitamin D Status and Cathelicidin Levels in Sepsis: A Randomized, Placebo-Controlled Trial.** Critical care medicine, 2015 Sep. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/26086941/>)
- [\[7\] **Significant Effects of Oral Phenylbutyrate and Vitamin D3 Adjunctive Therapy in Pulmonary Tuberculosis: A Randomized Controlled Trial.** PloS one, 2015. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/26394045/>)
- [\[8\] **Nasal Levels of Antimicrobial Peptides in Allergic Asthma Patients and Healthy Controls: Differences and Effect of a Short 1,25(OH)2 Vitamin D3 Treatment.** PloS one, 2015. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/26545199/>)
- [\[9\] **Cow's milk and rice fermented with Lactobacillus paracasei CBA L74 prevent infectious diseases in children: A randomized controlled trial.** Clinical nutrition (Edinburgh, Scotland), 2017 Feb. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/26732025/>)
- [\[10\] **Impact of high-dose vitamin D(3) on plasma free 25-hydroxyvitamin D concentrations and antimicrobial peptides in critically ill mechanically ventilated adults.** Nutrition (Burbank, Los Angeles County, Calif.), 2017 Jun. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/28526374/>)
- [\[11\] **Serum level of cathelicidin LL-37 in patients with active tuberculosis and other infectious diseases.** Journal of biological regulators and homeostatic agents, 2017 Jul-Sep. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/28956425/>)
- [\[12\] **Reduction of respiratory infections in asthma patients supplemented with vitamin D is related to increased serum IL-10 and IFNγ levels and cathelicidin expression.** Cytokine, 2018 Aug. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/29402723/>)
- [\[13\] **Vitamin D and Phenylbutyrate Supplementation Does Not Modulate Gut Derived Immune Activation in HIV-1.** Nutrients, 2019 Jul 21. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/31330899/>)
- [\[14\] **The therapeutic efficacy of Bifidobacterium animalis subsp. lactis BB-12(®) in infant colic: A randomised, double blind, placebo-controlled trial.** Alimentary pharmacology & therapeutics, 2020 Jan. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/31797399/>)
- [\[15\] **Therapeutic Potential of Cathelicidin Peptide LL-37, an Antimicrobial Agent, in a Murine Sepsis Model.** International journal of molecular sciences, 2020 Aug 19. review.](<https://pubmed.ncbi.nlm.nih.gov/32825174/>)
- [\[16\] **Seasonal Antimicrobial Activity of the Airway: Post-Hoc Analysis of a Randomized Placebo-Controlled Double-Blind Trial.** Nutrients, 2020 Aug 27. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/32867053/>)
- [\[17\] **A randomized controlled trial on the coloprotective effect of coenzyme Q10 on immune-inflammatory cytokines, oxidative status, antimicrobial peptides, and microRNA-146a expression in patients with mild-to-moderate ulcerative colitis.** European journal of nutrition, 2021 Sep. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/33620550/>)
- [\[18\] **Dose effect of bovine lactoferrin fortification on diarrhea and respiratory tract infections in weaned infants with anemia: A randomized, controlled trial.** Nutrition (Burbank, Los Angeles County, Calif.), 2021 Oct. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/34102559/>)
- [\[19\] **Impact of vitamin D status and cathelicidin antimicrobial peptide on adults with active pulmonary TB globally: A systematic review and meta-analysis.** PloS one, 2021. review.](<https://pubmed.ncbi.nlm.nih.gov/34115790/>)
- [\[20\] **Functional Antibodies and Innate Immune Responses to WRSS1, a Live Oral Shigella sonnei Vaccine Candidate, in Bangladeshi Adults and Children.** The Journal of infectious diseases, 2021 Dec 20. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/34374425/>)
- [\[21\] **Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial.** Wound repair and regeneration : official publication of the Wound Healing Society \[and\] the European Tissue Repair Society, 2021 Nov. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/34687253/>)
- [\[22\] **Reduction of Erythema in Moderate-Severe Rosacea by a Low Molecular Weight Heparan Sulfate Analog (HSA).** Journal of drugs in dermatology : JDD, 2023 Jun 1. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/37276169/>)
- [\[23\] **Efficacy of LL-37 cream in enhancing healing of diabetic foot ulcer: a randomized double-blind controlled trial.** Archives of dermatological research, 2023 Nov. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/37480520/>)
- [\[24\] **Efficacy and safety of Oral LL-37 against the Omicron BA.5.1.3 variant of SARS-COV-2: A randomized trial.** Journal of medical virology, 2023 Aug. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/37605995/>)
- [\[25\] **Effect of weekly vitamin D supplementation on the severity of atopic dermatitis and type 2 immunity biomarkers in children: A randomized controlled trial.** Journal of the European Academy of Dermatology and Venereology : JEADV, 2024 Sep. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/38483248/>)
- [\[26\] **Outcomes of High-Dose Versus Low-Dose Vitamin D on Prognosis of Sepsis Requiring Mechanical Ventilation: A Randomized Controlled Trial.** Journal of intensive care medicine, 2024 Oct. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/38706151/>)
- [\[27\] **Acute salivary antimicrobial peptide secretion response to different exercise intensities and durations.** American journal of physiology. Regulatory, integrative and comparative physiology, 2024 Dec 1. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/39155711/>)
- [\[28\] **Weekly Vitamin D Supplementation to Prevent Acute Respiratory Infections in Young Children at Different Latitudes: A Randomized Controlled Trial.** The Journal of pediatrics, 2024 Dec. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/39181322/>)
- [\[29\] **Associations between vitamin D status and biomarkers linked with inflammation in patients with asthma: a systematic review and meta-analysis of interventional and observational studies.** Respiratory research, 2024 Sep 19. review.](<https://pubmed.ncbi.nlm.nih.gov/39322954/>)
- [\[30\] **The Immunomodulatory Activity of High Doses of Vitamin D in Critical Care Patients with Severe SARS-CoV-2 Pneumonia-A Randomized Controlled Trial.** Nutrients, 2025 Jan 31. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/39940396/>)
- [\[31\] **Acute effects of continuous and interval cycling on salivary SIgA and anti-microbial peptide secretions: a randomized crossover trial.** European journal of applied physiology, 2026 Feb. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/40810749/>)
- [\[32\] **Limosilactobacillus fermentum LF61: A multidimensional study on safety and functionality from genomics to clinical application.** Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2026 May. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/41655688/>)
- [\[33\] **Cancer cell migration under control of human cathelicidin LL-37.** Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2026 May. review.](<https://pubmed.ncbi.nlm.nih.gov/41916132/>)
- [\[34\] **LL-37-ApoB-100 Complex Serves as a Biomarker of Coronary Artery Disease.** Arteriosclerosis, thrombosis, and vascular biology, 2026 Jun. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/41953980/>)
- [\[35\] **Role of Bruton's Tyrosine Kinase in mast cell driven urothelial barrier injury in an LL-37 induced model of interstitial cystitis.** Scientific reports, 2026 Apr 30. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/42062411/>)
- [\[36\] **Drugs@FDA/openFDA query for LL-37** U.S. Food and Drug Administration / openFDA. database query.](<https://api.fda.gov/drug/drugsfda.json?search=%22LL-37%22&limit=1>)
- [\[37\] **Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act** U.S. Food and Drug Administration, 2026-05-14. regulatory.](<https://www.fda.gov/media/94155/download>)
- [\[38\] **Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks** U.S. Food and Drug Administration, 2026-05. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- [\[39\] **Compounding and the FDA: Questions and Answers** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)
- [\[40\] **Efficacy of LL-37 Cream on Bacteria Colonization, Inflammation Response and Healing Rate of Diabetic Foot Ulcers** ClinicalTrials.gov. clinical trial registry.](<https://clinicaltrials.gov/study/NCT04098562>)
- [\[41\] **The 2026 List of Prohibited Substances and Methods** World Anti-Doping Agency, 2026. regulatory.](<https://ita.sport/resource/wada-2026-prohibited-list/>)
- [\[42\] **Safety of multiple administrations of spermicidal LL-37 antimicrobial peptide into the mouse female reproductive tract.** Molecular human reproduction, 2023 Jun 30. animal.](<https://pubmed.ncbi.nlm.nih.gov/37326833/>)
- [\[43\] **Antimicrobial host defence peptide, LL-37, as a potential vaginal contraceptive.** Human reproduction (Oxford, England), 2014 Apr. animal.](<https://pubmed.ncbi.nlm.nih.gov/24549217/>)
- [\[44\] **Cathelicidin LL-37 restoring glucocorticoid function in smoking and lipopolysaccharide-induced airway inflammation in rats.** Chinese medical journal, 2019 Mar 05. animal.](<https://pubmed.ncbi.nlm.nih.gov/30741829/>)
- [\[45\] **Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial.** Wound Repair and Regeneration, 2022. human clinical.](<https://pmc.ncbi.nlm.nih.gov/articles/PMC9298190/>)

[PepFlow library coverage](<https://pepflow.app/research/peptide-library/>)

## Quick facts

**Family**

Immune signaling peptide

**Tier**

D

**Evidence**

42% Preliminary

**Safety**

Limited Data

**FDA status**

Not Approved

**Topical 503A**

Flagged

**Citations**

[45 citations](<https://pepflow.app/peptides/ll-37/#published-research>)

**Updated**

October 25, 2026

### Potential benefits

- Antimicrobial defense
- Skin and barrier inflammation
- Wound healing
- Gut barrier support

### Common side effects

- Local irritation

### Also known as

- LL-37
- Cathelicidin
- hCAP18-derived LL-37
- Human cathelicidin antimicrobial peptide

## Related

- [Peptide Label Key](<https://pepflow.app/peptide-label-legend/>)
- [LL-37 dosage guide](<https://pepflow.app/peptides/ll-37/dosage/>)
- [PepFlow Library Statistics (2026) · 65 Profiles](<https://pepflow.app/research/peptide-library/>)
